# Risk Adapted SABR(SABR) in Stage I NSCLC And Lung Metastases

> **NCT01823003** · PHASE2 · UNKNOWN · sponsor: **Institut Català d'Oncologia** · enrollment: 67 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Neoplasm Metastasis

## Interventions

- **RADIATION:** 34 Gy in a single fraction
- **RADIATION:** 54Gy 18Gy/fr. x 3 fractions
- **RADIATION:** 60Gy (12 x 5 fr.s)
- **RADIATION:** 60Gy (7.5Gy x 8fr.)

## Key facts

- **NCT ID:** NCT01823003
- **Lead sponsor:** Institut Català d'Oncologia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-06
- **Primary completion:** 2019-12
- **Final completion:** 2020-07
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2019-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01823003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01823003, "Risk Adapted SABR(SABR) in Stage I NSCLC And Lung Metastases". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01823003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*